Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT04659044 · Academic and Community Cancer Research United · PHASE2 · terminated · last registry update 2024-09-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial closed due to low accrual rate” | – | Registry record, Academic and Community Cancer Research United |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD79B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-18Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab Vedotin (NCT03677141)
- 2024-08-26Results posted on the registry: City of Hope Medical Center, Carboplatin + Etoposide (NCT04665765)
- 2024-07-26Phase 3 first posted: Ruijin Hospital, polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide + zanubrutinib, rituximab and lenalidomide (NCT06522555)
- 2024-07-11Also stopped (terminated): Hoffmann-La Roche, Venetoclax + Polatuzumab Vedotin (NCT04790903)
- 2024-05-21Also stopped (withdrawn): Fondazione Italiana Linfomi - ETS, R-DHAP + Pola-R-DHAP (NCT05966233)
- 2023-12-26Results posted on the registry: Hoffmann-La Roche, Lenalidomide + Obinutuzumab (NCT02600897)
- 2023-10-10Results posted on the registry: Hoffmann-La Roche, Obinutuzumab + Rituximab (NCT02611323)
- 2023-09-21Phase 3 first posted: Hoffmann-La Roche, Glofitamab + Polatuzumab vedotin (NCT06047080)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision